MSD

Merck & Co. Breaks Ground on $1 Billion Biologics Center in US

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future US home for Keytruda.

MSD to Buy B-Cell Depletion Therapy from Curon

Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.

Daiichi Sankyo and MSD Expand Global Collaboration

Japan's Daiichi Sankyo and US drugmaker MSD have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody drug conjugates to include MSD’s MK-6070, a compound MSD obtained through its recent acquisition of Harpoon Therapeutics.

MSD to Acquire EyeBio for up to $3 Billion

US drugmaker Merck & Co. (MSD) has agreed to acquire privately held ophthalmology-focused biotechnology company Eyebiotech (EyeBio).

Merck & Co. to Acquire Harpoon Therapeutics for $680 Million

US Merck & Co., known as MSD outside of North America, intends to buy cancer drug developer Harpoon Therapeutics for $23.00 per share in cash for an approximate equity value of $680 million.

MSD Ireland Opens New Site in Dunboyne, Completes Expansion in Carlow

In Ireland, US drugmaker MSD has opened its new facility in Dunboyne, County Meath, and has expanded its Carlow site. MSD says it has invested more than €1 billion at both sites, creating 670 new jobs and increasing the number of employees in Ireland to 3,100. 100 of the newly created positions remain to be filled.

Astex and MSD Expand Drug Discovery Collaboration

UK-based Astex Pharmaceuticals, specialized in the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced an exclusive worldwide research collaboration and license agreement with US drugmaker MSD (in the US, the company trades as Merck & Co).

Artificial Intelligence for New Drug Design

Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.

Made in Switzerland – Exported Worldwide

US Merck and F-star in Cancer Collaboration

UK Watchdog Accuses Merck of Breaking Competition Law

Sanofi and MSD End Vaccines JV

Proteros Signs Second Oncology Collaboration with MSD

Quality and Efficiency in Pharma Manufacturing

Russia’s and Eastern Europe’s Booming Pharma Industry

Merck & Co. Commences Tender Offer for Inspire Pharmaceuticals